Hepatitis B Community
Abstracts from APASLD2012
About This Community:

This forum is an un-mediated, patient-to-patient forum for questions and support regarding Hepatitis B. Topics in this forum include but are not limited to, Causes, Diagnosis, Family and Relationships, Living With Hepatitis B, Research Updates, Treatment, Success Stories, Support, Symptoms.

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

Abstracts from APASLD2012

The abstracts are now available from the Hepatology International Journal, but access is restricted to registered members. Does anyone have membership?
http://www.springerlink.com/content/n70m780mw054/
Related Discussions
7 Comments Post a Comment
Blank
Avatar_m_tn
.... or maybe a alternative path to be able to see the abstracts :)
Blank
Avatar_m_tn
Please we are waiting...
Blank
Avatar_m_tn
Only one I manage to get so far.

Here is the abstract about REP 9AC from APASLD 2012 Conference in Taiwan:

REP 9AC / REP 9AC’: Potent HBsAg release inhibitors that can rapidly elicit durable immunological control of infection in patients with chronic hepatitis B
Mamun-Al-Mahtab1, Michel Bazinet2 and Andrew Vaillant2
1Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2REPLICor Inc., Montreal, Canada
BACKGROUND: HBsAg suppresses host immunity and permits chronicity of HBV infection. REP9AC / REP9AC’ are nucleic acid-based polymers (NAPs) that block HBsAg release from infected hepatocytes. The current clinical results with REP9AC and a 4th generation NAP (REP9AC’) are disclosed.
METHODS: Patients with pre-treatment HBV DNA titers between 106 and 1012 copies/ml were treated by IV infusion. Virologic response was assessed using the Cobas and Architect testing platforms.
RESULTS (REP9AC): > 99.5% reduction of HBsAg occurred in seven of eight patients within 7 days to 32 weeks of treatment. All responders achieved 3 - 7 log reductions in HBV DNA. Four responders achieved complete control of their infection with 20-44 weeks of treatment (HBV DNA < 500cpm). Off treatment, three patients had sustained immunological control of their infection (HBV DNA < 500cpm, and HBsAg  90% reductions in HBsAg and 2-7 log reductions in HBV DNA). Mild pro-inflammatory side-effects accompanied drug administration.
RESULTS (REP9AC’): REP9AC’ is more stable with reduced pro-inflammatory activity compared to REP9AC. Interim data show robust HBsAg reductions in all seven patients in the first 10 weeks of treatment. Three patients have already experienced a 3-4 log decline in HBV DNA. Pro-inflammatory side-effects during administration were substantially reduced.
CONCLUSIONS: NAPs can affect rapid clearance of HBsAg, allowing restoration of host immunity. These results suggest that NAPs may become an important new tool in the treatment of chronic hepatitis B.
Blank
Avatar_m_tn
http://www.natap.org/2012/APASL/APASL.htm

is this what you are looking for ? (don't had time to look over, but at first look looks like it is )
Blank
Avatar_m_tn
on the second one - i saw that only one doc is referring to the HBV
Blank
Avatar_m_tn
Thanks. I did have a look. It certainly provides some of the abstracts that natap consider useful. Hopefully, they will have more soon.
Blank
Avatar_m_tn
http://www.lorenti.ch/apph/index.php?option=com_content&view=article&id=118&Itemid=132

link is from APPH 2011presetnation  - but have some good information
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources
RSS Expert Activity
469720_tn?1388149949
Blank
Abdominal Aortic Aneurysm-treatable... Blank
Oct 04 by Lee Kirksey, MDBlank
242532_tn?1269553979
Blank
The 3 Essentials to Ending Emotiona...
Sep 18 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Control Emotional Eating with this ...
Sep 04 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
Avatar_m_tn
Blank
stef2011
Italy
Avatar_m_tn
Blank
StephenCastlecrag
Australia
Avatar_m_tn
Blank
veteranB
CA
9624973_tn?1413019730
Blank
melcul
United Kingdom
Avatar_m_tn
Blank
SafiSifa
Izmir, Turkey
Avatar_m_tn
Blank
mer971